



LeMaitre Continues to Expand Direct-to-Hospital Sales; Latest Conversions to Include New Zealand and Finland

June 30, 2015

BURLINGTON, Mass., June 30, 2015 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it has begun selling Direct-to-Hospital in New Zealand and will be converting Finland as of January 2016.

"We continue to leverage our international presence as we transition countries away from distributors and through our direct sales channel instead," said George W. LeMaitre, Chairman and CEO. "Selling direct allows us to build closer relationships with our vascular surgeon customers, including the opportunity to offer our full complement of products."

With the conversion of these two countries, LeMaitre will have direct sales to hospitals in 21 countries, up from 14 in 2010. To prepare for the go-direct initiative in New Zealand, the Company hired its first sales person, who will be supported by the Melbourne office. In Finland, the Company plans to leverage its Nordics manager in support of a Helsinki-based sales person.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at <http://www.lemaitre.com>.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk that the Company may not achieve success in the named countries and other risks and uncertainties included under the heading "Risk Factors" in its most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at <http://www.lemaitre.com> and on the SEC's website at <http://www.sec.gov>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Contact: LeMaitre Vascular, Inc.

Beth Kurth

+1-781-425-1659

bkurth@lemaitre.com

<http://www.lemaitre.com>

 Primary Logo

LeMaitre Vascular, Inc.